Arizona's New Naloxone Isn't a Gift — It's a Price Pharma Set for Itself

Arizona is getting two new shipments of free naloxone this fall, and neither one is being paid for in cash.

Under the Hikma Pharmaceuticals settlement, the state is set to receive 6,599 units of nasal naloxone — each unit two doses — with delivery expected before the end of September 2026. A separate deal with Amneal Pharmaceuticals, part of a $272.5 million nationwide opioid settlement, sends Arizona 33,714 units over four years starting this year, about 8,428 units annually, with the first delivery also timed for September.

Both are “in-kind” settlements: instead of paying Arizona cash for the harm its opioids caused, the manufacturer hands over product. On paper it reads as generosity. In practice, the company that owes the debt also gets to decide what the debt is worth.

Arizona took the naloxone because it was the deal on the table, not because the arithmetic favors the state.

Filter’s reporting on the Amneal settlement lays out exactly how that arithmetic works against communities. Amneal values its settlement naloxone at $125 per two-dose kit — the list price nobody actually pays — which caps its $180 million naloxone obligation at 1.44 million kits nationwide. The same company sells the identical product to the state of California for $24 a kit. At California’s price, that $180 million would buy 7.5 million kits instead — more than five times the naloxone reaching more people. A cash settlement would let states buy at the real price. An in-kind one lets the manufacturer set the price it’s graded on.

None of this makes the Hikma or Amneal units useless once they land. Arizona already has the pipeline: Teva’s ongoing settlement obligation shipped 55,442 units to the state in 2024-25 alone, routed through 13 counties and community groups that report more than 500 overdose reversals tied to the program. The new units will move through the same channels, governed by the One Arizona Agreement, which splits settlement dollars 56 percent to counties and cities and 44 percent to the state — money local governments, not manufacturers, decide how to spend. Maricopa County put $4.3 million of that cash toward 17 organizations this year for naloxone access, outreach, and treatment.

That local control is precisely what in-kind naloxone bypasses. Arlene Mahoney, who runs the peer-led Southwest Recovery Alliance in Phoenix, spent this summer fighting a City Council push to restrict cheaper intramuscular naloxone in favor of the pricier nasal spray — the same format Hikma and Amneal are shipping. “A seatbelt is harm reduction,” she told Lookout, arguing communities should choose the equipment that fits, not have it dictated to them.

If you carry naloxone, or you’re the reason someone in your family still does, that choice is being made for you twice over — once by a manufacturer pricing its own debt, and once by a council deciding which version you’re allowed to have. Arizona will take the units. It shouldn’t mistake them for the settlement it was actually owed.